Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Recommendation of “Hold” from Brokerages

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has been given an average recommendation of “Hold” by the twenty-seven ratings firms that are covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a sell recommendation, thirteen have given a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $24.7727.

Several equities analysts have commented on SRPT shares. Wells Fargo & Company lowered their price objective on shares of Sarepta Therapeutics from $45.00 to $38.00 and set an “overweight” rating for the company in a research report on Friday, February 27th. Citigroup increased their price objective on shares of Sarepta Therapeutics from $9.00 to $13.00 and gave the company a “sell” rating in a research report on Thursday, March 26th. HC Wainwright reiterated a “sell” rating on shares of Sarepta Therapeutics in a research report on Thursday, April 16th. Wall Street Zen upgraded shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, Mizuho increased their price objective on shares of Sarepta Therapeutics from $26.00 to $31.00 and gave the company an “outperform” rating in a research report on Thursday, March 12th.

Sarepta Therapeutics Price Performance

SRPT stock opened at $15.89 on Wednesday. Sarepta Therapeutics has a 52 week low of $10.41 and a 52 week high of $40.90. The company has a quick ratio of 2.62, a current ratio of 4.63 and a debt-to-equity ratio of 0.56. The company has a fifty day simple moving average of $19.61 and a two-hundred day simple moving average of $19.81. The firm has a market capitalization of $1.68 billion, a P/E ratio of -16.55, a price-to-earnings-growth ratio of 0.16 and a beta of 0.21.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $3.16 EPS for the quarter, beating the consensus estimate of $0.98 by $2.18. Sarepta Therapeutics had a negative net margin of 2.94% and a positive return on equity of 7.56%. The business had revenue of $730.80 million during the quarter, compared to analyst estimates of $474.16 million. During the same quarter last year, the business earned ($3.42) earnings per share. Sarepta Therapeutics’s quarterly revenue was down 1.9% compared to the same quarter last year. Analysts anticipate that Sarepta Therapeutics will post 3.99 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Stephen Mayo sold 7,239 shares of the firm’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $17.02, for a total value of $123,207.78. Following the completion of the sale, the director owned 1,765 shares in the company, valued at approximately $30,040.30. This trade represents a 80.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Several institutional investors have recently made changes to their positions in the company. Yousif Capital Management LLC lifted its holdings in shares of Sarepta Therapeutics by 1.9% in the 4th quarter. Yousif Capital Management LLC now owns 25,704 shares of the biotechnology company’s stock worth $541,000 after acquiring an additional 481 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Sarepta Therapeutics by 7.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 8,751 shares of the biotechnology company’s stock worth $190,000 after acquiring an additional 636 shares during the last quarter. Arizona State Retirement System lifted its holdings in shares of Sarepta Therapeutics by 2.8% in the 3rd quarter. Arizona State Retirement System now owns 26,165 shares of the biotechnology company’s stock worth $504,000 after acquiring an additional 717 shares during the last quarter. Sound View Wealth Advisors Group LLC lifted its holdings in shares of Sarepta Therapeutics by 6.1% in the 3rd quarter. Sound View Wealth Advisors Group LLC now owns 12,695 shares of the biotechnology company’s stock worth $245,000 after acquiring an additional 728 shares during the last quarter. Finally, Thrivent Financial for Lutherans lifted its holdings in shares of Sarepta Therapeutics by 3.3% in the 2nd quarter. Thrivent Financial for Lutherans now owns 23,140 shares of the biotechnology company’s stock worth $396,000 after acquiring an additional 744 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.